EP 3893899 A2 20211020 - CHIMERIC ANTIGEN RECEPTORS AND CAR-T CELLS AND METHODS OF USE
Title (en)
CHIMERIC ANTIGEN RECEPTORS AND CAR-T CELLS AND METHODS OF USE
Title (de)
CHIMÄRE ANTIGEN-REZEPTOREN UND CAR-T-ZELLEN UND VERWENDUNGSVERFAHREN
Title (fr)
RÉCEPTEURS ANTIGÉNIQUES CHIMÉRIQUES ET RÉCEPTEURS DE LYMPHOCYTES T ET MÉTHODES D'UTILISATION
Publication
Application
Priority
- US 201862778893 P 20181212
- US 2019065776 W 20191211
Abstract (en)
[origin: WO2020123691A2] Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD 19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD 19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CDl9 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.
IPC 8 full level
A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61P 35/02 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01)
CPC (source: EP IL KR US)
A61K 39/4611 (2023.05 - EP IL KR US); A61K 39/4631 (2023.05 - EP IL KR US); A61K 39/4644 (2023.05 - KR); A61K 39/464412 (2023.05 - EP IL US); A61K 39/464424 (2023.05 - EP IL US); A61K 2239/29 (2023.05 - US); A61K 2239/31 (2023.05 - US); A61K 2239/38 (2023.05 - US); A61P 35/00 (2018.01 - IL US); A61P 35/02 (2018.01 - EP IL KR); A61P 35/04 (2018.01 - KR); C07K 14/7051 (2013.01 - EP IL); C07K 16/2803 (2013.01 - EP IL KR US); C07K 16/2887 (2013.01 - EP IL KR US); C07K 16/2896 (2013.01 - US); C12N 5/0636 (2013.01 - EP IL US); C12N 5/10 (2013.01 - US); C12N 15/63 (2013.01 - US); A61K 2039/505 (2013.01 - EP IL KR); A61K 2121/00 (2013.01 - KR); A61K 2239/29 (2023.05 - EP IL); A61K 2239/31 (2023.05 - EP IL); A61K 2239/38 (2023.05 - EP IL); A61K 2300/00 (2013.01 - KR); C07K 2317/24 (2013.01 - US); C07K 2317/31 (2013.01 - EP IL KR); C07K 2317/35 (2013.01 - EP IL KR); C07K 2317/56 (2013.01 - US); C07K 2317/565 (2013.01 - US); C07K 2317/622 (2013.01 - EP IL KR US); C07K 2317/73 (2013.01 - US); C07K 2317/76 (2013.01 - US); C07K 2319/03 (2013.01 - EP IL KR); C07K 2319/33 (2013.01 - EP IL KR); C12N 2510/00 (2013.01 - KR)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2020123691 A2 20200618; WO 2020123691 A3 20200723; AR 117685 A1 20210825; AU 2019397033 A1 20210722; AU 2019397033 B2 20230629; AU 2023233053 A1 20231005; BR 112021012172 A2 20210831; CA 3122762 A1 20200618; CA 3177829 A1 20200618; CN 113412117 A 20210917; EP 3893899 A2 20211020; IL 283734 A 20210729; JP 2022513778 A 20220209; JP 2023169138 A 20231129; JP 7386382 B2 20231127; KR 20210102941 A 20210820; MX 2021006968 A 20211013; SG 11202106302W A 20210729; TW 202039563 A 20201101; TW 202140567 A 20211101; US 11793834 B2 20231024; US 2020246382 A1 20200806; US 2024115611 A1 20240411
DOCDB simple family (application)
US 2019065776 W 20191211; AR P190103635 A 20191212; AU 2019397033 A 20191211; AU 2023233053 A 20230918; BR 112021012172 A 20191211; CA 3122762 A 20191211; CA 3177829 A 20191211; CN 201980091506 A 20191211; EP 19836733 A 20191211; IL 28373421 A 20210606; JP 2021533159 A 20191211; JP 2023110377 A 20230705; KR 20217021608 A 20191211; MX 2021006968 A 20191211; SG 11202106302W A 20191211; TW 108145595 A 20191212; TW 110125603 A 20191212; US 201916711180 A 20191211; US 202318470745 A 20230920